Belite Bio(US:BLTE)2025-08-11 20:30Financial Performance - Total operating expenses increased to $17596 thousand in Q2 2025 from $10471 thousand in Q2 2024[13] - Research and Development (R&D) expenses increased to $11049 thousand in Q2 2025 from $9078 thousand in Q2 2024[13] - General and Administrative (G&A) expenses increased significantly to $6547 thousand in Q2 2025 from $1393 thousand in Q2 2024[13] - Net loss increased to $16320 thousand in Q2 2025 from $9494 thousand in Q2 2024[13] - The company had $1492 million in cash, liquidity fund, time deposits and U S treasury bills[13] - The company raised approximately $15 million in gross proceeds in a registered direct offering on August 8, 2025[13] Pipeline and Clinical Trials - Belite Bio is conducting a Phase 3, 2-year global trial ("PHOENIX" Study) for Stargardt Disease (STGD1) with completed enrollment of 529 subjects[10] - A Phase 3, 2-year global trial ("DRAGON" Study) is ongoing for Tinlarebant with 104 subjects aged 12-20, with completion expected in Q4 2025[10] - A Phase 2/3, 2-year global trial ("DRAGON II" Study) is ongoing for Tinlarebant with 60 subjects aged 12-20[10] Tinlarebant - Tinlarebant is a novel, once-daily oral tablet designed to reduce retinol delivery to the eye by binding to serum retinol binding protein 4 (RBP4)[11] - Belite Bio believes early intervention targeting emerging retinal pathology is the best approach to slow disease progression in STGD1 & GA[11]